ANAB Stock Analysis: Buy, Sell, or Hold?
ANAB - AnaptysBio, Inc. Common Stock
$62.19
-0.50 (-0.79%)
▼
5d:
-7.12%
30d:
-8.4%
90d:
+13.28%
HOLD
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Distribution
ANAB is up 8.1% this week, but smart money is buying puts. Top strike: $50 2026-06-18 with 2,020 OI. Put ratio: 98% View Scanner →
Strength: 8.9/10
Get Alerted When ANAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ANAB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ANAB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$127.47
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$79.15
21.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ANAB is currently trading at $62.19, which is considered fair relative to its 30-day fair value range of $58.64 to $69.99. The stock's valuation (Forward PE: 12.7) is in line with its historical norms (13.4). Remarkably, the market is currently pricing in an annual earnings decline of 1.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ANAB is in a strong uptrend. Immediate support is located at $57.85, while resistance sits at $72.36.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $81.36 (+30.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ANAB is in a strong uptrend. Immediate support is located at $57.85, while resistance sits at $72.36.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $81.36 (+30.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$58.64 -
$69.99
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.8% below Wall St target ($81.36)
- CAUTION: Recommendation downgraded due to -7.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$58.64 -
$69.99
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$7.06
(11.4%)
Support & Resistance Levels
Support Level
$57.85
Resistance Level
$72.36
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.73
Wall Street Target
$81.36
(+30.8%)
Revenue Growth (YoY)
-8.0%
Profit Margin
-11.5%
Valuation Discount vs History
-1.8% cheaper
PE vs Historical
12.7 vs 13.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.8%
(market-implied from PE analysis)
1-Year Target
$61.07
(-2%)
2-Year Target
$59.97
(-4%)
3-Year Target
$58.89
(-5%)
3-Yr Target (if PE normalizes)
(PE: 13→13)
$61.99
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 449.3%)
$363.36
(+484%)
Base:
(SPY PE: 12.7, Growth: 449.3%)
$209.89
(+238%)
Bear:
(PE: 10.8, Growth: 449.3%)
$178.41
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.7 to 13.4
Stabilization Target:
$65.46
(+5.3%)
PE Expansion Potential:
+5.3%
Share & Embed Analysis
Last updated: May 14, 2026 10:47 PM ET
Data refreshes hourly during market hours. Next update: 11:47 PM
Data refreshes hourly during market hours. Next update: 11:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
John P Schmid
SELL
20645 shares
2026-03-30
Daniel Faga
SELL
17679 shares
2026-03-27
Eric J Loumeau
SELL
10000 shares
2026-02-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 58 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 58 HOLD |